leadf
logo-loader
viewReckitt Benckiser

SocGen double-downgrades Reckitt Benckiser rating to ‘sell’ from ‘buy’ on margin concerns

The French bank's analysts said the blue-chip company needs to "cross the chasm" into mass market positions to reignite growth, which should impact on its margins

Dettol bottle
They forecast Reckitt’s margins contracting by 180 bp (basis points) to less than 25% by 2021

Societe Generale has double-downgraded its rating for FTSE 100-listed consumer goods firm Reckitt Benckiser Group PLC (LON:RB.) to ‘sell’ from ‘buy’ on margin concerns.

The French broker also cut its target price for the Dettol disinfectant to Nurofen painkillers firm to 5,600p from 7,300p, with the shares down 0.3% to 6,345p in morning trade.

READ: Reckitt poaches Pepsi's chief commercial officer to be new boss

In a note to clients, SocGen’s analysts said the company needs to "cross the chasm" into mass market positions to reignite growth, which should impact on its margins.

They forecast Reckitt’s margins contracting by 180 bp (basis points) to less than 25% by 2021.

The analysts said they do not expect the group’s 2.9% full-year 2018 growth to be improved on this year, as Reckitt’s underlying sales growth has been 2.5%-3.0% per annum for the past five years.

They added that they see Reckitt posting organic sales growth of 2.5% in full-year 2019.

Quick facts: Reckitt Benckiser

Price: 7470 GBX

LSE:RB.
Market: LSE
Market Cap: £53.14 billion
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

GinsGlobal Managing Director sees Healthcare and Healthcare innovation as...

HANetf and GinsGlobal Index Funds' Managing Director Anthony Ginsberg joined Steve Darling from Proactive to share details about the success of their Healthcare Innovations ETF. Ginsberg discusses how COVID-19 had made a direct impact on that fund, especially in the telemedicine...

14 hours, 10 minutes ago

2 min read